The Role of Cyclin Dependent Kinase Inhibitor 3 () in Promoting Human Tumors: Literature Review and Pan-cancer Analysis

Overview

Journal Heliyon

Specialty Social Sciences

Date 2024 Feb 21

PMID 38380029

Authors

Chuanlong Zhang

Qian Shen

Mengqi Gao

Junchen Li

Bo Pang

Affiliations

Soon will be listed here.

Abstract

Background: Although many experiments and clinical studies have proved the link between the expression of and human tumors, we have not been able to identify any bioinformatics study in which the extensive tumor-promoting effect of was systematically analyzed.

Objective: Explore the extensive tumor-promoting effects of and review the research progress of in cancer.

Methods: We systematically reviewed the literature on and tumors. We explored the potential tumor-promoting effects of on different tumors in the TCGA database and the GTEx database using multiple platforms and websites. We studied the expression level of , survival, prognosis, diagnosis, genetic variation, immune infiltration, and enrichment analysis using databases such as TIMER 2.0, GEPIA2, cBioPortal, and STRING.

Results: We found that is highly expressed in most tumors. The expression of is closely related to the prognosis of some tumors. And may have diagnostic value. The conclusion of our literature review is roughly the same, but there are differences, which are worthy of further study. Moreover, may be related to immune cell infiltration in tumor tissues. The genetic alteration of LUAD, STAD, SARC, PCPG, and ESCA with "Amplification" as the main type. In addition, through enrichment analysis, we found that affects tumors mainly through the control of the cell cycle and mitosis.

Conclusion: is highly expressed in most tumor tissues and has a statistical correlation with survival prognosis. It has extensive tumor-promoting effects that may be related to mechanisms such as immune infiltration.

Citing Articles

Identification of CDKN3 overexpression as a marker of poor prognosis and potential therapeutic target in low-grade glioma.

Cheng H, Meng X, Zhang Y, Wang P, Lu Y Sci Rep. 2025; 15(1):2679.

PMID: 39838029 PMC: 11751337. DOI: 10.1038/s41598-025-86338-8.

HDAC1: a promising target for cancer treatment: insights from a thorough analysis of tumor functions.

Xie J, Liu R, Cai Y, Liu D Transl Cancer Res. 2024; 13(10):5300-5315.

PMID: 39525004 PMC: 11543092. DOI: 10.21037/tcr-24-23.

References

Wu M, Liu Z, Zhang A, Li N . Identification of key genes and pathways in hepatocellular carcinoma: A preliminary bioinformatics analysis. Medicine (Baltimore). 2019; 98(5):e14287. PMC: 6380748. DOI: 10.1097/MD.0000000000014287. View

Wu Q, Zhang B, Wang Z, Hu X, Sun Y, Xu R . Integrated bioinformatics analysis reveals novel key biomarkers and potential candidate small molecule drugs in gastric cancer. Pathol Res Pract. 2019; 215(5):1038-1048. DOI: 10.1016/j.prp.2019.02.012. View

Steven A, Seliger B . The Role of Immune Escape and Immune Cell Infiltration in Breast Cancer. Breast Care (Basel). 2018; 13(1):16-21. PMC: 6016054. DOI: 10.1159/000486585. View

Shinden Y, Hirashima T, Nohata N, Toda H, Okada R, Asai S . Molecular pathogenesis of breast cancer: impact of miR-99a-5p and miR-99a-3p regulation on oncogenic genes. J Hum Genet. 2020; 66(5):519-534. DOI: 10.1038/s10038-020-00865-y. View

Cress W, Yu P, Wu J . Expression and alternative splicing of the cyclin-dependent kinase inhibitor-3 gene in human cancer. Int J Biochem Cell Biol. 2017; 91(Pt B):98-101. PMC: 5641230. DOI: 10.1016/j.biocel.2017.05.013. View

Li R, Mei S, Ding Q, Wang Q, Yu L, Zi F . A pan-cancer analysis of the role of hexokinase II (HK2) in human tumors. Sci Rep. 2022; 12(1):18807. PMC: 9637150. DOI: 10.1038/s41598-022-23598-8. View

Wei W, Lv Y, Gan Z, Zhang Y, Han X, Xu Z . Identification of key genes involved in the metastasis of clear cell renal cell carcinoma. Oncol Lett. 2019; 17(5):4321-4328. PMC: 6447949. DOI: 10.3892/ol.2019.10130. View

Liu X, Wu J, Zhang D, Bing Z, Tian J, Ni M . Identification of Potential Key Genes Associated With the Pathogenesis and Prognosis of Gastric Cancer Based on Integrated Bioinformatics Analysis. Front Genet. 2018; 9:265. PMC: 6056647. DOI: 10.3389/fgene.2018.00265. View

Li H, Jiang X, Yu Y, Huang W, Xing H, Agar N . KAP regulates ROCK2 and Cdk2 in an RNA-activated glioblastoma invasion pathway. Oncogene. 2014; 34(11):1432-41. DOI: 10.1038/onc.2014.49. View

10.

Wang J, Wang Y, Xu J, Song Q, Shangguan J, Xue M . Global analysis of gene expression signature and diagnostic/prognostic biomarker identification of hepatocellular carcinoma. Sci Prog. 2021; 104(3):368504211029429. PMC: 10450782. DOI: 10.1177/00368504211029429. View

11.

Abdel-Tawab M, Fouad H, Othman A, Eid R, Mohammed M, Hassan A . Evaluation of gene expression of PLEKHS1, AADAC, and CDKN3 as novel genomic markers in gastric carcinoma. PLoS One. 2022; 17(4):e0265184. PMC: 9022821. DOI: 10.1371/journal.pone.0265184. View

12.

Ge X, Wang Z, Jiang R, Ren S, Wang W, Wu B . SCAMP4 is a novel prognostic marker and correlated with the tumor progression and immune infiltration in glioma. Int J Biochem Cell Biol. 2021; 139:106054. DOI: 10.1016/j.biocel.2021.106054. View

13.

Hao N, Zhou Y, Li Y, Zhang H, Wang B, Liu X . Clinical Value and Potential Mechanisms of Oxysterol-Binding Protein Like 3 (OSBPL3) in Human Tumors. Front Mol Biosci. 2021; 8:739978. PMC: 8560696. DOI: 10.3389/fmolb.2021.739978. View

14.

Lee Y, Tan Y, Oon C . Molecular targeted therapy: Treating cancer with specificity. Eur J Pharmacol. 2018; 834:188-196. DOI: 10.1016/j.ejphar.2018.07.034. View

15.

Cui X, Zhang X, Liu M, Zhao C, Zhang N, Ren Y . A pan-cancer analysis of the oncogenic role of staphylococcal nuclease domain-containing protein 1 (SND1) in human tumors. Genomics. 2020; 112(6):3958-3967. DOI: 10.1016/j.ygeno.2020.06.044. View

16.

Yang J, Zhang A, Luo H, Ma C . Construction and validation of a novel gene signature for predicting the prognosis of osteosarcoma. Sci Rep. 2022; 12(1):1279. PMC: 8786962. DOI: 10.1038/s41598-022-05341-5. View

17.

Ma Z, Liu Y, Hao Z, Hua X, Li W . DNA hypermethylation of aurora kinase A in hepatitis C virus‑positive hepatocellular carcinoma. Mol Med Rep. 2019; 20(3):2519-2532. PMC: 6691273. DOI: 10.3892/mmr.2019.10487. View

18.

Liu D, Zhang J, Wu Y, Shi G, Yuan H, Lu Z . YY1 suppresses proliferation and migration of pancreatic ductal adenocarcinoma by regulating the CDKN3/MdM2/P53/P21 signaling pathway. Int J Cancer. 2017; 142(7):1392-1404. DOI: 10.1002/ijc.31173. View

19.

Chen X, Song E . Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discov. 2018; 18(2):99-115. DOI: 10.1038/s41573-018-0004-1. View

20.

Yang B, Luo L, Luo W, Zhou Y, Yang C, Xiong T . The genomic dynamics during progression of lung adenocarcinomas. J Hum Genet. 2017; 62(8):783-788. PMC: 5537414. DOI: 10.1038/jhg.2017.40. View